1 Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2021;71,209–249.
2 McCormick BZ, Mahmoud AM, Williams SB, Davis JW. Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies. Indian J. Urol. 2019;35.
3 Armstrong WR, et al. Comparison of recurrence patterns after surgery and radiation therapy with 68Ga-PSMA-11 PET/CT in nonmetastatic castrate-sensitive prostate cancer patients: A single-center post-hoc retrospective analysis in 787 patients. J. Clin. Oncol. 2020;38,3577–3577.
4 Quero L, et al. 18F-Choline PET/CT and Prostate MRI for Staging Patients With Biochemical Relapse After Irradiation for Prostate Cancer. Clin. Nucl. Med. 2015;40,e492–e495.
5 Hennequin C, Hannoun-Lévi JM, Rozet F. Management of local relapse after prostate cancer radiotherapy: Surgery or radiotherapy? Cancer/Radiothérapie 2017;21,433–436.
6 Park YH, et al. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis: LATE RECURRENCE OF RCC. BJU Int. 2012;110, E553–E558.
7 Spyropoulou D, et al. Radiotherapy and Renal Cell Carcinoma: A Continuing Saga. In Vivo 2021;35,1365–1377.
8 Slaton JW, Swanson DA, Grossman HB, Dinney CPN. A STAGE SPECIFIC APPROACH TO TUMOR SURVEILLANCE AFTER RADICAL CYSTECTOMY FOR TRANSITIONAL CELL CARCINOMA OF THE BLADDER. J. Urol. 1999;162,710–714.
9 Koh DM, Husband JE. Patterns of recurrence of bladder carcinoma following radical cystectomy. Cancer Imaging. 2003;3(2):96–100.
10 van Rhijn BWG, van der Poel HG, van der Kwast TH. Urine Markers for Bladder Cancer Surveillance: A Systematic Review. Eur. Urol. 2005;47,736–748.
11 Merriel SWD, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022;20,54.
12 Roberts MJ, et al. Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. Urology 2017;104,11–21.
13 Zhu CZ, Ting HN, Ng KH, Ong TA. A review on the accuracy of bladder cancer detection methods. J. Cancer 2019;10,4038–4044.
14 Heijnsdijk EAM, et al. Cost-effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data. JNCI J. Natl. Cancer Inst. 2015;107.
15 Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic — implementation issues and future challenges. Nat. Rev. Clin. Oncol. 2021;18,297–312.
16 Springer SU, et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. eLife 2018;7,e32143.
17 Mattila KE, Vainio P, Jaakkola PM. Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy. Cancers 2022;14,239.
18 Sumanasuriya S. et al. Consensus statement on circulating biomarkers for advanced prostate cancer. J. Clin. Oncol. 2018;36,299–299.
19 Velders M, et al. Exercise is a potent stimulus for enhancing circulating DNase activity. Clin. Biochem. 2014;47,471–474.
20 Misale S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486,532–536.